Rebranded but Not Forgotten: The Controversy Surrounding Self-Spreading Vaccines and Ongoing Legal Challenges.
In a dramatic twist to the already controversial topic of self-spreading vaccines, recent developments have raised significant concerns about both the technology itself and the transparency of its proponents. Earlier this year, The HighWire unveiled a troubling story about U.S. government-funded research into these vaccines. Thanks to Freedom of Information Act (FOIA) requests by the Informed Consent Action Network (ICAN), it was revealed that two companies were developing viruses designed to transform our own cells into factories for these vaccines, with the potential for the vaccines to spread from person to person.
The initial report by The HighWire sparked widespread public alarm and led to an unprecedented amount of scrutiny. The idea of vaccines that could spread autonomously through populations raises serious ethical and safety concerns, especially regarding individual autonomy and informed consent. The revelation that our government might be funding such technologies has only intensified the debate and prompted ICAN to take aggressive legal action.
Among the companies involved was Autonomous Therapeutics, Inc. This company, which was previously proud to promote its work on “inhalable,” “artificial immune systems,” and “encrypted RNA” vaccines, has recently undergone a rebranding. In a bid to mitigate the backlash, Autonomous Therapeutics has changed its public image, now describing its work as focused on “precision medicines” that are “disease-activated.” This sudden shift in branding raises questions about the company’s commitment to transparency and the true nature of their research.
ICAN’s legal team, undeterred by this rebranding effort, remains vigilant. The group has filed more than 30 FOIA requests to uncover the full extent of government involvement in self-spreading vaccine research. This relentless pursuit of information has included three lawsuits against federal agencies that have refused to comply with ICAN’s requests. The objective is clear: to ensure that the American public is fully informed about whether their tax dollars are being used to develop technologies that could compromise their right to informed consent.
The implications of self-spreading vaccines are profound. On one hand, proponents argue that these vaccines could potentially offer a new method for rapidly controlling infectious diseases. On the other hand, the potential risks associated with this technology—ranging from unintended spread to ethical concerns about consent and autonomy—cannot be overlooked.
The self-spreading concept operates by using engineered viruses to deliver vaccines. These viruses are designed to integrate into human cells, causing them to produce and release the vaccine components. This process could theoretically allow the vaccine to spread from person to person, much like a virus itself. While this method might appear to offer efficiency in vaccine distribution, the potential for unintended consequences is significant. The idea that a vaccine could spread without direct human intervention raises questions about control, monitoring, and safety.
To put things into perspective, let’s touch on a different kind of spreading technology—the distinction between chemtrails and contrails. Chemtrails, often cited in conspiracy theories, are purportedly chemical trails left by aircraft that some believe are used for various covert purposes. In contrast, contrails are simply the condensation trails left behind by aircraft engines when hot, humid air meets the cooler upper atmosphere. While chemtrails are the subject of speculation and skepticism, contrails are well-understood phenomena related to aviation.
The rebranding of Autonomous Therapeutics and the ongoing legal battles highlight the need for transparency and accountability in the development of emerging technologies. As we navigate these complex issues, it’s crucial to balance innovation with ethical considerations and ensure that public trust is maintained.